RATIONALE: Although serotonin (5-HT) dysregulation is implicated in the pathophysiology of major depressive disorder (MDD), the role of specific receptor subtypes remains to be elucidated. Emerging preclinical research suggests an important role for the 5-HT(1B) receptor in behavioral regulation and depressive phenotypes. In particular, 5-HT(1B) heteroreceptors located within the striatum have been shown to play an essential role in antidepressant action. OBJECTIVES: The objective of this study was to determine 5-HT(1B) receptor binding potential (BP (ND)) in the region of the ventral striatum/ventral pallidum (VS/VP) in individuals with MDD and healthy control participants. METHODS: Ten participants with MDD (30.8 ± 9.5 years, five men/five women) in a current major depressive episode (MDE) and ten healthy control participants (30.7 ± 10.5 years, five men/five women) underwent positron emission tomography (PET) scanning with the selective 5-HT(1B) receptor radioligand [(11)C]P943. RESULTS: Within the VS/VP region of interest, [(11)C]P943 BP (ND) was significantly reduced in the MDD group compared with the healthy control group (1.37 ± 0.13 and 1.68 ± 0.16, respectively; 18.7% between-group difference; p < 0.001). CONCLUSIONS: Consistent with preclinical and postmortem data, our findings suggest abnormally reduced function of VS/VP 5-HT(1B) receptors in humans with MDD. Abnormal 5-HT(1B) heteroreceptor function may contribute to dysfunctional reward signaling within the striatum, including the nucleus accumbens, via interaction with dopamine, γ-amino-butyric acid, or glutamate systems. Our findings suggest reduced 5-HT(1B) receptor signaling in the VS/VP in MDD and contribute to the therapeutic rationale for testing 5-HT(1B) agonists as a novel class of antidepressants.
RATIONALE: Although serotonin (5-HT) dysregulation is implicated in the pathophysiology of major depressive disorder (MDD), the role of specific receptor subtypes remains to be elucidated. Emerging preclinical research suggests an important role for the 5-HT(1B) receptor in behavioral regulation and depressive phenotypes. In particular, 5-HT(1B) heteroreceptors located within the striatum have been shown to play an essential role in antidepressant action. OBJECTIVES: The objective of this study was to determine 5-HT(1B) receptor binding potential (BP (ND)) in the region of the ventral striatum/ventral pallidum (VS/VP) in individuals with MDD and healthy control participants. METHODS: Ten participants with MDD (30.8 ± 9.5 years, five men/five women) in a current major depressive episode (MDE) and ten healthy control participants (30.7 ± 10.5 years, five men/five women) underwent positron emission tomography (PET) scanning with the selective 5-HT(1B) receptor radioligand [(11)C]P943. RESULTS: Within the VS/VP region of interest, [(11)C]P943 BP (ND) was significantly reduced in the MDD group compared with the healthy control group (1.37 ± 0.13 and 1.68 ± 0.16, respectively; 18.7% between-group difference; p < 0.001). CONCLUSIONS: Consistent with preclinical and postmortem data, our findings suggest abnormally reduced function of VS/VP 5-HT(1B) receptors in humans with MDD. Abnormal 5-HT(1B) heteroreceptor function may contribute to dysfunctional reward signaling within the striatum, including the nucleus accumbens, via interaction with dopamine, γ-amino-butyric acid, or glutamate systems. Our findings suggest reduced 5-HT(1B) receptor signaling in the VS/VP in MDD and contribute to the therapeutic rationale for testing 5-HT(1B) agonists as a novel class of antidepressants.
Authors: N Tzourio-Mazoyer; B Landeau; D Papathanassiou; F Crivello; O Etard; N Delcroix; B Mazoyer; M Joliot Journal: Neuroimage Date: 2002-01 Impact factor: 6.556
Authors: W C Drevets; E Frank; J C Price; D J Kupfer; D Holt; P J Greer; Y Huang; C Gautier; C Mathis Journal: Biol Psychiatry Date: 1999-11-15 Impact factor: 13.382
Authors: Alexander Neumeister; Allison C Nugent; Tracy Waldeck; Marilla Geraci; Markus Schwarz; Omer Bonne; Earle E Bain; David A Luckenbaugh; Peter Herscovitch; Dennis S Charney; Wayne C Drevets Journal: Arch Gen Psychiatry Date: 2004-08
Authors: Katherine M Nautiyal; Laurent Tritschler; Susanne E Ahmari; Denis J David; Alain M Gardier; René Hen Journal: Neuropsychopharmacology Date: 2016-06-29 Impact factor: 7.853
Authors: Christopher Pittenger; Thomas G Adams; Jean-Dominique Gallezot; Michael J Crowley; Nabeel Nabulsi; Hong Gao; Stephen A Kichuk; Ryan Simpson; Eileen Billingslea; Jonas Hannestad; Michael Bloch; Linda Mayes; Zubin Bhagwagar; Richard E Carson Journal: J Affect Disord Date: 2016-02-09 Impact factor: 4.839
Authors: Katarina Varnäs; Svante Nyberg; Per Karlsson; M Edward Pierson; Matts Kågedal; Zsolt Cselényi; Dennis McCarthy; Alan Xiao; Minli Zhang; Christer Halldin; Lars Farde Journal: Psychopharmacology (Berl) Date: 2011-01-15 Impact factor: 4.530
Authors: Aybala Saricicek; Jason Chen; Beata Planeta; Barbara Ruf; Kalyani Subramanyam; Kathleen Maloney; David Matuskey; David Labaree; Lorenz Deserno; Alexander Neumeister; John H Krystal; Jean-Dominique Gallezot; Yiyun Huang; Richard E Carson; Zubin Bhagwagar Journal: Eur J Nucl Med Mol Imaging Date: 2014-11-27 Impact factor: 9.236
Authors: David Matuskey; Zubin Bhagwagar; Beata Planeta; Brian Pittman; Jean-Dominique Gallezot; Jason Chen; Jane Wanyiri; Soheila Najafzadeh; Jim Ropchan; Paul Geha; Yiyun Huang; Marc N Potenza; Alexander Neumeister; Richard E Carson; Robert T Malison Journal: Biol Psychiatry Date: 2013-11-28 Impact factor: 13.382